Disappointing Trial Results Impact Sanofi's Stock

On this episode of Stock Movers:
- Sanofi’s experimental drug for the skin condition atopic dermatitis disappointed investors in a late stage trial, after the benefit of the drug was less than expected.
- Jet2 fell 25%. Trading volume was six times the average for this time of day. The stock reversed the previous session's gain.
- A year after losing its spot in Britain’s blue-chip benchmark, Burberry is returning to the UK’s stock-market elite. The luxury-goods maker, best known for its tartan-plaid trench coats, will rejoin the FTSE 100 Index later this month, index compiler FTSE Russell said Wednesday.

See omnystudio.com/listener for privacy information.